Biosketch - Winship Cancer Institute - Emory University

spongereasonInternet and Web Development

Nov 12, 2013 (4 years ago)

96 views





Principal Investigator/Program Director
(Last, first, middle):






PHS 398/2590 (Rev.
09/04
)
(Reissued 4/2006)

Page


Biographical Sketch Format Page


BIOGRAPHICAL SKETCH


NAME

Dong M. Shin, M.D.

POSITION TITLE

Professor of Hematology and Oncology
, Otolaryngology

EDUCATION/TRAINING

INSTITUTION AND LOCATION

DEGREE

YEAR(s)

FIELD OF STUDY

Yonsei University, Seoul, Korea


1971

Pre
-
Med

Yonsei Univ
ersity, College of Medicine, Seoul, Korea

MD

1975

Medicine

Cook County Hospital, Chicago, IL

Residency

1985

Internal Medicine

University of Texas M.D. Anderson Cancer Center
,
Houston, TX

Fellowship

1988

Medical Oncology


A.

Positions and Honors.


1988
-
1989

Univ. of
Texas M.D. Anderson Cancer Center, Department of Medical Oncology,

Faculty
Associate, Houston, TX

1989
-
1991

Univ. of Texas M.D. Anderson Cancer Center, Department of Medical Oncology,

Clinical
Instructor of Medicine, Houston, TX

1991
-
1996

Univ. of Texas M.D. Anderso
n Cancer Center, Department of Medical Oncology,

Section of
Head, Neck and Thoracic Medical Oncology; Assistant Professor of Medicine, Houston, TX

1997
-
2001

Univ. of Texas M.D. Anderson Cancer Center, Department of Medical Oncology,




Section of Head, N
eck and Thoracic Medical Oncology; Associate Professor of Medicine,
Houston, TX

2001
-
2003

Univ. of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute;




Professor of Medicine and Otolaryngology, Pittsburgh, PA

2003
-
Present

Winship
Cancer Institute, Director, Clinical and Translational Cancer Prevention Program,
Co
-


Director, Translational Aerodigestive Tract Malignancies Program,
Associate Director of
Academic Development, Winship Cancer Institute,
Emory University School

of
M
edi
cine;
Professor of Hematology and Oncology,
and Otolaryngology,
Atlanta, GA.


B.

Selected peer
-
reviewed publications (in chronological order) from more than 1
4
0 articles.

1.

Shin DM
, Chiao PJ, Sacks PG, Shin HJ, Hittelman W, and Tainsky M: Activation of the ri
bosomal
protein S2 genes in a hamster model of chemically induced oral carcinogenesis. Carcinogenesis
14:163
-
166, 1993.

2.

Voravud N,
Shin DM
, Ro JY, Lee JS, Hong WK, and Hittelman WN: Increased polysomies of
chromosomes 7 and 17 during head and neck multis
tage tumorigenesis. Cancer Res 53:2874
-
2833,
1993.

3.

Shin DM
, Voravud N, Ro JY, Lee JS, Hong WK, and Hittelman WN: Sequential upregulation of
proliferating cell nuclear antigen in head and neck tumorigenesis: a potential biomarker.
J Natl Cancer
Inst
85:97
1
-
978, 1993.

4.

Perez
-
Soler R, Donato NJ,
Shin DM
, Rosemblum MG, Zhang H
-
Z, Tornos C, Brewer H, Shah T, Chan
JC, Thompson LB, Janus M, Lee JS, Hong WK, Murray JL: Tumor epidermal growth factor receptor
studies in patients with non
-
small cell lung cancer of h
ead and neck cancer treated with monoclonal
antibody RG 83852. J Clin Oncol 12:730
-
739, 1994.

5.

Shin DM
, Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor
expression in multistep procell or head and neck tumorigenesis. Cancer

Res 534:3153
-
3159, 1994.

6.

Shin DM
, Kim JG, RO JY, Roth JA, Hong WK, and Hittelman WN: Activation of p53 gene in
premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321
-
326, 1994.

7.

Shin DM
, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyn
e K, Shin HJ, Goefert H, Hong WK,
Hittelman WN. P
-
53 expression: Predicting recurrence and secondary tumors in head and neck
Squamous cell carcinomas. J Natl Cancer Inst 88:519
-
529, 1996.





Principal Investigator/Program Director
(Last, first, middle):






PHS 398/2590 (Rev.
09/04
)
(Reissued 4/2006)

Page


Biographical Sketch Format Page


8.

Shin DM
, Xu
-
XC, Lippman SM, Lee JS, Batsakis JG, Ro JY, Hittelman WN
, Lotan R, Hong WK.

Accumulation of p53 protein and retinoic acid receptor

β in retinoid chemoprevention. Clin Cancer Res
3:875
-
880, 1997.

9.

Shin DM
, Mao L, Papadimitrakopoulou V, Clayman G, El
-
Naggar A, Shin HJC, Lee JJ, Lee JS,
Gillenwater A, Myers J, Lippman SM, Hittelman

WN, and Hong WK: Alteration of p53 gene and protein
by biochemopreventive therapy in patients with advanced premalignant lesions in the upper
aerodigestive tract. J Natl Cancer Inst. 92:69
-
73, 2000.

10.

Shin DM
, Donato NJ, Perez
-
Soler R, Shin HJ, Ji Y Wu, Zh
ang P, Khuri FR, Glisson BS, Pfister D,
Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor targeted therapy with
humanized chimeric monoclonal antibody, C225 in combination with cisplatin in patients with head and
neck cancer. Cli
n Cancer Res, 7:1204
-
1213, 2001.

11.

Shin DM,
Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L,
Papadimi Trakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goefert H, Hong
K. Combined interferon
-

, 13
-
ci
s
-
retinoic acid and

-
tocopherol in locally advanced head and neck
Squamous cell carcinoma: Novel Bioadjuvant Phase II trial. J Clin Oncol 19:3010
-
3017, 2001.

12.

Shin DM
, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK, Hittelman WN. P53 peotein
accumulatin a
nd genomic instability in head and neck tumorigenesis. Cancer Epidemiol Biomarkers &
Prev 10:603
-
609, 2001.

13.

Kim J,
Shin DM,
El
-
Naggar A, Lee JS, Corrales C, Lippman SM, Hong WK, Hittelman WN. Genetic
instability and histologic characteristics in oral prem
alignant lesions. Cancer Epidemiol Biomarkers &
Prev 10:319
-
325, 2001.

14.

Shin DM
, Glisson BS, Khuri FR
,

Clifford JL, Clayman G, Benner Se, Forastiere AA, Ginsberg L, Liu D,
Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic stud
y of
interferon
-

, 13
-
cis
-
retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20:364
-
370, 2002.

15.

Shin DM
, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimtrakooulou V, Feng L,
Francisco M, Garden A, Kies MS, Myers J, Cla
yman G, Hong WK. Phase II Study of Induction
Chemotherapy with Paclitaxel, Ifosfamide, and Carboplatin (TIC) for Patients with Locally Advanced
Squamous Cell Carcinoma of the Head and Neck.
Cancer
95:340
-
353, 2002.

16.

Rhee JC, Khuri FR,
Shin DM
.
Emerging dr
ugs for head and neck cancer. Expert Opinion



Emerging drugs, Vol. 9, No. 1, 91
-
104, 2004.

17.

Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR
, Shin DM
: Simultaneous targeting epidermal
growth factor receptor tyrosine kinase and Cyclooxygenase
-
2, an ef
ficient approach to inhibition of
squamous cell carcinoma of the head and neck. Clin Cancer Res, 10:5930
-
5939, 2004.

18.

Zhang X, Hunt JL, Lansittel DP, Adler
-
Storthy K, Ferris R,
Shin DM
, Chen Z: A role of protease
-
activated receptor
-
1 (PAR
-
1) on lymph nod
e metastasis via induction of differentiation in squamous cell
carcinoma of the head an
d neck Clin Cancer Res, 10:8451
-
2459, 2004
.

19.

Zhang X, Chen Z, Choe MS, Lin Y, Wieand HS, Shin HJ, Chen A, Khuri FR,

Shin DM.

Tumor growth
inhibition by simultaneously blo
cking EGFR and cycloosygenase
-
2 in a xenograft mode
l. Clin Cancer
Res
, 11:6261
-
6269, 2005.

20.

Choe MS, Zhang X, Shin HJ,
Shin DM
, Chen Z. Interaction between EGFR signaling and COX
-
2
pathways and its therapeutic implications. Mol Cancer Therap
4(9):1448
-
145
5, 2005
.

21.

Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM
, Cohen RB, Jones C, Sur R, Raben D, Jassem J,
Ove R, Kies M, Baselga J, Amellal N, Rowinsky EK, Ang KK. Cetuximan plus radiotherapy for locally
advanced squamous cell carcinoma of head and neck, N
ew Eng J Med, 354: 567
-
579, 2006.

22.

Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B,
Shenouda G, Hodson I, Fu K,
Shin DM
, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase
III trail of low
-
dose isotretinoin for
prevention of second primary tumors in stage I and II head and neck
cancer patients. J Nat Cancer Ins, 98: 441
-
50, 2006.

23.

Bonner JA
,
Harari PM
,
Giralt J
,
Azarnia N
,
Shin DM
,
Cohen RB
,
Jones CU
,
Sur R
,
Raben D
,
Jassem J
,
Ove R
,
Kies MS
,
Baselga J
,
Youssoufian H
,
Amellal N
,
Rowinsky EK
,
Ang KK
.
Radiotherapy plus
cetuximab for squamous
-
cell carcinoma of the head and neck
. New Engl J Med 354:567
-
579, 2006.





Principal Investigator/Program Director
(Last, first, middle):






PHS 398/2590 (Rev.
09/04
)
(Reissued 4/2006)

Page


Biographical Sketch Format Page


24.

Sinha R, Kim G, Nie S,
Shin DM
: Nanotechnology in Cancer Therapeutics: Bioconjug
ated
Nanoparticles for Drug Delivery.
Mol Cancer Ther
(In press)
.


C. Research Support.



Project Number (Principal Investigator):

U01CA101244 (Shin)

Source:

NIH/NCI

My role:

PI

Title of Project (and/or Subproject):

Chemoprevention of Head and Neck Cancer

with ZD1839
and Celecoxib for Former Smokers

Dates of Approved/proposed project:

4/01/03
-
3/31/08

Overall goals: To investigate efficacy and toxicity of a combination of EGFR
-
tyrosine kinase inhibitor, ZD1839
and COX
-
2 inhibitor, Celecoxib
,

in patients wi
th premalignant lesions of the oral cavity and larynx in former
smoke
rs. We
will also investigate the relevant biomarkers in this project.


Project Number (Principal Investigator):


Source:

Georgia Cancer Coalition

My role:

PI

Title of Project (and/or Sub
project):

Georgia Cancer Coalition Distinguished Scholar

Dates of Approved/proposed project:

2005
-
2010

Overall goals: To develop and complete research for tobacco related malignancies.


Project Number (Principal Investigator):

GT 04111512

(Shin)

Source:

Georgia Technical Institute

My role:

PI

Title of Project (and/or Subproject):

A Novel Methodology in the Detection of Biomarkers by an
Acoustic Wave Biosensor in Head and Neck Cancer.

Dates of Approved/proposed project:

01/01/05
-
12/31/05

Overlap:

None

Over
all goals:
To study the methodology for the detection of biomarkers by an Acoustic Wave Biosensor in
Head and

Neck Cancer.


Project Number (Principal Investigator):

RFA CA 05 024 (Shin)

Source:

CCNE (Project 5)

My role:

PI

Title of Project (and/or Subproj
ect):

Nanotherapeutics: Multifunctional Nanoparticles for Drug
Delivery and Targeting

Dates of Approved/proposed project:

10/01/05
-
9/30/10


Overlap:

None

Overall goals:
To develop a new class of self
-
assembled and biodegradable Nanoparticles for delivery
and
targeting of cytotoxic chemotherapeutic drugs to solid tumors.


Active

Project Number (Principal Investigator):

NCI CA R01 112643

Source:

NIH/NCI

My role:

PI

Title of Project (and/or Subproject):

Second primary tumor prevention with EGFR TKIs and COX
-
2 Inhibitors in Head and Neck Cancer.

Dates of Approved/proposed project:

7/01/05
-
6/31/10

Overall goals: To study second primary tumor prevention using EGFR TKIs and COX
-
2 Inhibitors